Source: Manufacturer webpage
UNIVERSE clinical trial
- n = 112 (Final n = 98, 64 Rivaroxaban, 34 Aspirin)
- Randomized 2:1 (Rivaroxaban : Aspirin)
- Open label Rivaroxaban vs. Usual Aspirin.
- Age 2-8 yrs
- Follow up for 12 months.
Some images worth learning from are posted here (Note: Most of them are plagiarised. But, sources are referenced)
Source: Manufacturer webpage
UNIVERSE clinical trial
1) Sotrovimab IV (GSK) - Monoclonal antibodies - reduces hospitalization by 90%, effective against Omicron variant.
2) Oral Paxlovid (Nirmatlevir/Ritonavir, Pfizer) - x 5 days - reduces hospitalization by 90%.
3) Remdesvir IV (Gilead) - x 3 days - reduces hospitalization by 90%.
4) Oral Molnupiravir (Merck) - x 5 days - reduces hospitalization by 30%.
Basis of classification:These are based on peak static and dynamic components achieved during competition. Higher values may be reached during training.Dynamic component - estimated % of Max O2 and cardiac output.Static component - estimated Maximal voluntary contraction (MVC) reached/results in high BP.
*Danger of bodily collision† Increased risk if syncope occurs+ AAP classifies cricket in I-B